Prognostic Factors for Progression-free Survival (PFS), Overall Survival (OS), and Long-term OS (LT-OS) With Sunitinib in 1,059 Patients, Treated on Clinical Trials, With Metastatic Renal Cell Carcinoma (mRCC)

被引：0
|
作者：
Motzer, R. J. [1 ]
Escudier, B. [2 ]
Bukowski, R. [3 ]
Rini, B. I. [3 ]
Hutson, T. E. [4 ]
Barrios, C. H. [5 ]
Lin, X. [6 ]
Fly, K. [7 ]
Matczak, E. [8 ]
Gore, M. E. [9 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Med, Villejuif, France
[2] Inst Gustave Roussy, Immunotherapy Unit, Villejuif, France
[3] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA
[4] Baylor Sammons Canc Ctr Texas Oncol, Dallas, TX USA
[5] PUCRS Sch Med Hematol & Oncol, Porto Alegre, RS, Brazil
[6] Pfizer Oncol, Clin Stat, La Jolla, CA USA
[7] Pfizer Oncol, Oncol, New London, CT USA
[8] Pfizer Oncol, Oncol, New York, NY USA
[9] Royal Marsden Hosp NHS Trust, London, England
来源：
EUROPEAN JOURNAL OF CANCER | 2011年 / 47卷
关键词：
D O I：
10.1016/S0959-8049(11)70649-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S98 / S99
页数：2
相关论文
共 50 条
  • [31] PROGRESSION-FREE SURVIVAL (PFS) IS CORRELATED WITH OVERALL SURVIVAL (OS) IN CLINICAL STUDIES OF TARGETED THERAPIES PLUS CHEMOTHERAPY IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (mCRC)
    Sidhu, Roger
    Rong, Alan
    Dahlberg, Steve
    ANNALS OF ONCOLOGY, 2011, 22 : v120 - v120
  • [32] Progression-free survival (PFS) as a surrogate for overall survival (OS) in patients with advanced colorectal cancer: An analysis of 3159 patients randomized in 11 trials.
    Buyse, M
    Burzykowski, T
    Carroll, K
    Michiels, S
    Pignon, JP
    Piedbois, P
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 249S - 249S
  • [33] Effect of bisphosphonates (Bis) combined with sunitinib (Su) on the response rate (RR), progression-free survival (PFS), and overall survival (OS) of patients (pts) with bone metastases (mets) from renal cell carcinoma (RCC).
    Keizman, Daniel
    Ish-Shalom, Maya
    Taksey, Jason David
    Pili, Roberto
    Hammers, Hans J.
    Eisenberger, Mario A.
    Boursi, Ben
    Berger, Raanan
    Maimon, Natalie
    Gottfried, Maya
    Hayat, Henry
    Peer, Avivit
    Kovel, Svetlana
    Sella, Avishay
    Carducci, Michael Anthony
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [34] Calculators for overall survival (OS) and progression-free survival (PFS) in metastatic colorectal cancer (mCRC): Construction from 19,678 ARCAD patients
    Sjoquist, Katrin Marie
    Bokemeyer, Carsten
    Renfro, Lindsay A.
    Simes, John
    Tebbutt, Niall C.
    Clarke, Stephen John
    Adams, Richard
    Punt, Cornelis J. A.
    Van Cutsem, Eric
    Douillard, Jean-Yves
    Hecht, J. Randolph
    Heinemann, Volker
    Sougklakos, Ioannis
    Diaz-Rubio, Eduardo
    Porschen, Rainer
    Meyers, Jeffrey P.
    Gonsalves, Wilson I.
    Sargent, Daniel J.
    De Gramont, Aimery
    Zalcberg, John Raymond
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [35] RELATIONSHIP BETWEEN PROGRESSION-FREE (PFS) AND OVERALL SURVIVAL (OS) IN I-LINE RANDOMIZED CLINICAL TRIALS (RCT) FOR ADVANCED RENAL CELL CARCINOMA (RCC): CORRELATION AND POWER ANALYSIS
    Bria, E.
    Massari, F.
    Maines, F.
    Bonomi, M.
    Porta, C.
    Bracarda, S.
    Cognetti, F.
    Giannarelli, D.
    Tortora, G.
    Milella, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 273 - 273
  • [36] PROGRESSION-FREE AND OVERALL SURVIVAL OF PATIENTS TREATED WITH PRESURGICAL SUNITINIB PRIOR TO CYTOREDUCTIVE NEPHRECTOMY (CN) IN CLEAR CELL SYNCHRONOUS METASTATIC RENAL CELL CARCINOMA (MRCC)
    Bex, Axel
    Blank, Christian
    Chowdhury, Simon
    Nichol, David
    Peters, John
    Horenblas, Simon
    O'Brien, Tim
    Sarwar, Naveed
    Haanen, John
    Powles, Thomas
    JOURNAL OF UROLOGY, 2011, 185 (04): : E709 - E710
  • [37] Progression-free survival (PFS) and overall survival (OS) in patients (pts) with mismatch repair deficient (dMMR) solid tumors treated with dostarlimab in the GARNET study
    Andre, T.
    Berton-Rigaud, D.
    Curigliano, G.
    Sabatier, R.
    Tinker, A. V.
    Oaknin, A.
    De Braud, F. G. M.
    Ellard, S.
    Arkenau, H-T.
    Trigo Perez, J. M.
    Brown, J.
    Jewell, A.
    Pikiel, J.
    Mirza, M. R.
    Duan, T.
    Antony, G.
    Zildjian, S.
    Zografos, E.
    Veneris, J.
    Banerjee, S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S799 - S800
  • [38] Use of bisphosphonates (Bis) combined with sunitinib (Su) to improve the response rate (RR), progression-free survival (PFS), and overall survival (OS) of patients (pts) with bone metastases (mets) from renal cell carcinoma (RCC)
    Peer, Avivit
    Ish-Shalom, Maya
    Hammers, Hans J.
    Eisenberger, Mario A.
    Sinibaldi, Victoria J.
    Pili, Roberto
    Maimon, Natalie
    Gottfried, Maya
    Hayat, Henry
    Kovel, Svetlana
    Sella, Avishay
    Neumann, Avivit
    Boursi, Ben
    Berger, Raanan
    Carducci, Michael Anthony
    Keizman, Daniel
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [39] Progression-free survival (PFS) and overall survival (OS) in phase HI trials of systemic chemotherapy in advanced non-small cell lung cancer (NSCLC).
    Hotta, K.
    Kiura, K.
    Takigawa, N.
    Tabata, M.
    Fujiwara, Y.
    Tanimoto, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [40] Nomograms for overall survival (OS) and progression-free survival (PFS) in metastatic colorectal cancer (mCRC): Construction from 19,678 ARCAD patients.
    Sjoquist, Katrin Marie
    Renfro, Lindsay A.
    Simes, John
    Tebbutt, Niall C.
    Clarke, Stephen John
    Meyers, Jeffrey P.
    Gonsalves, Wilson I.
    Adams, Richard
    Seymour, Matthew T.
    Saltz, Leonard
    Schmoll, Hans
    Sargent, Daniel J.
    De Gramont, Aimery
    Zalcberg, John Raymond
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
12345